81 related articles for article (PubMed ID: 16164207)
1. [Regulation of osteoclastogenesis by activated T cells].
Sato K; Takayanagi H
Nihon Rinsho; 2005 Sep; 63(9):1529-32. PubMed ID: 16164207
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis.
Udagawa N
J Bone Miner Metab; 2003; 21(6):337-43. PubMed ID: 14586789
[TBL] [Abstract][Full Text] [Related]
3. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL.
Kotake S; Nanke Y; Mogi M; Kawamoto M; Furuya T; Yago T; Kobashigawa T; Togari A; Kamatani N
Eur J Immunol; 2005 Nov; 35(11):3353-63. PubMed ID: 16220542
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes.
Miranda-Carús ME; Benito-Miguel M; Balsa A; Cobo-Ibáñez T; Pérez de Ayala C; Pascual-Salcedo D; Martín-Mola E
Arthritis Rheum; 2006 Apr; 54(4):1151-64. PubMed ID: 16575870
[TBL] [Abstract][Full Text] [Related]
6. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis.
Kelchtermans H; Geboes L; Mitera T; Huskens D; Leclercq G; Matthys P
Ann Rheum Dis; 2009 May; 68(5):744-50. PubMed ID: 18480308
[TBL] [Abstract][Full Text] [Related]
7. Effects of activated T cells on osteoclastogenesis depend on how they are activated.
Wyzga N; Varghese S; Wikel S; Canalis E; Sylvester FA
Bone; 2004 Sep; 35(3):614-20. PubMed ID: 15336596
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
9. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
11. Osteoclasts, rheumatoid arthritis, and osteoimmunology.
Sato K; Takayanagi H
Curr Opin Rheumatol; 2006 Jul; 18(4):419-26. PubMed ID: 16763464
[TBL] [Abstract][Full Text] [Related]
12. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
13. Activated T lymphocytes support osteoclast formation in vitro.
Horwood NJ; Kartsogiannis V; Quinn JM; Romas E; Martin TJ; Gillespie MT
Biochem Biophys Res Commun; 1999 Nov; 265(1):144-50. PubMed ID: 10548505
[TBL] [Abstract][Full Text] [Related]
14. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms.
Weitzmann MN; Cenci S; Rifas L; Haug J; Dipersio J; Pacifici R
J Bone Miner Res; 2001 Feb; 16(2):328-37. PubMed ID: 11204433
[TBL] [Abstract][Full Text] [Related]
15. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
16. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular interactions between immune system and bone.
Grcević D; Katavić V; Lukić IK; Kovacić N; Lorenzo JA; Marusić A
Croat Med J; 2001 Aug; 42(4):384-92. PubMed ID: 11471190
[TBL] [Abstract][Full Text] [Related]
19. Interplay between interferon and other cytokine systems in bone metabolism.
Takayanagi H; Sato K; Takaoka A; Taniguchi T
Immunol Rev; 2005 Dec; 208():181-93. PubMed ID: 16313349
[TBL] [Abstract][Full Text] [Related]
20. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
